



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Docket No: A7517

Richard ARMITAGE et al

Conf. No.: 7400

Appln. No.: 09/322,021

Group Art Unit: 1644

Filed: May 28, 1999

Examiner: Gambel, P.

For: MOUSE CD40 LIGAND-SPECIFIC
ANTIBODIES AND HYBRIDOMAS

STATEMENT OF SUBSTANCE OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks summarizing the interview conducted on May 10, 2007:

REMARKS

An Examiner's Interview Summary Record (PTO-413) was attached with the Notice of Allowance/Allowability dated August 3, 2007.

During interview, the status of the application subsequent to Judgment and Reconstruction was discussed:

The Examiner indicated that a Notice of Allowance was forthcoming upon updated search. Further, the Examiner and Applicants' agreed to update the priority information in the specification by Examiner's Amendment.

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

STATEMENT OF SUBSTANCE OF INTERVIEW
U.S. Appln. No. 09/322,021 (A7517)

It is believed that no petition or fee is required. However, if the U.S. Patent and Trademark Office deems otherwise, Applicants hereby petition for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER


Gordon Kit

Registration No. 30,764

Date: August 13, 2007